Evofem Biosciences Inc (EVFM)
0.0128
0.00 (0.00%)
USD |
OTCM |
Apr 23, 15:58
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.5898M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -99.55% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.1327 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -0.6505 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. |
| URL | https://www.evofem.com |
| Investor Relations URL | http://investors.neothetics.com/phoenix.zhtml?c=253672&p=irol-IRHome |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Apr. 26, 2024 (est.) |
| Last Earnings Release | Nov. 14, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. |
| URL | https://www.evofem.com |
| Investor Relations URL | http://investors.neothetics.com/phoenix.zhtml?c=253672&p=irol-IRHome |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Apr. 26, 2024 (est.) |
| Last Earnings Release | Nov. 14, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |